Day 3 Recap: SBS 2025

To stay informed with the latest conference insights, subscribe to receive our eNewsletters.

Four Key Factors When Buying Dermatology Devices

Following his discussion and demonstration at the 2025 South Beach Symposium, Suneel Chilukuri, MD, a board-certified dermatologist from Houston, Texas, shared insights with Dermatology Times on non-CME devices and innovations. He addressed distinctions between FDA-cleared and FDA-approved devices, emphasizing the importance of safety and efficacy in clinical practice.

Balancing Steroid and Non-Steroid Treatments

A prevalent concern among both patients and clinicians is the belief that steroids are inherently harmful. Lio emphasized that while caution is necessary, these medications remain an essential component of dermatologic care. "I think one of the biggest misconceptions is that steroids are the enemy, and we feel pretty confident in saying that they are not," he explained. "They can be used safely. They are very, very accessible for patients. They're very reliable. They help almost everybody." However, he stressed the importance of responsible usage, advising practitioners to "use them sparingly and in a targeted fashion."

Efficient Screening for Psoriatic Arthritis

At the 2025 South Beach Symposium, Naiem Issa, MD, PhD, FAAD, a board-certified dermatologist with Forefront Dermatology in Vienna, Virginia, shared insights into the challenges of diagnosing and managing psoriatic arthritis in dermatology clinics. He emphasized the importance of efficient screening methods to identify patients at risk, given the often busy nature of dermatology practices.

How Emerging Therapies Are Changing the AD Treatment Landscape

In a recent interview with Dermatology Times, Emma Guttman, MD, PhD, discussed biologics for atopic dermatitis (AD), the focus of her presentation at the 2025 South Beach Symposium. As the chair of the department of dermatology at the Icahn School of Medicine at Mount Sinai in New York City, Guttman shared valuable insights on new and upcoming therapies for the condition, as well as patient best practices. Guttman and her team at Icahn see roughly two thirds of dermatology patients in the city of New York and has become1 of the 3 largest departments in the United States.

Updates in Clinical Study of Patients of Color

One of the key challenges in dermatologic clinical trials is the lack of trust between clinicians and patients, particularly among individuals from diverse backgrounds. Mona Shahriari, MD, FAAD, emphasized that many patients from these communities have historical reasons for their skepticism, as they were often the subjects of unethical medical practices. Because of this, she advocates for offering clinical trial participation as an option rather than pushing patients into it, allowing trust to build over time.

Advancing Acne Care: New Therapies and Technologies

Christopher Bunick, MD, PhD, associate professor of dermatology and translational biomedicine at Yale School of Medicine, recently discussed advancements in acne and rosacea treatments during an interview with Dermatology Times at the 2025 South Beach Symposium in Miami, Florida. As the medical chair of the symposium’s curriculum, Bunick provided insights into innovative therapeutic approaches for inflammatory skin conditions.

PsA Management: Psoriasis Beyond Skin Symptoms

Kircik highlighted the significance of asking simple yet effective questions to identify potential joint involvement in psoriasis patients. "It takes less than a minute to ask the patient, do you have difficulty getting out of the car while you drive an hour or two?Do you have difficulty getting out of bed in the morning?" he explained. He says these questions can serve as an entry point to educating patients about the systemic nature of psoriasis and psoriatic arthritis.